1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €2.62 (+3,053,513.05%). The median is €2.62 (+3,053,513.05%).
| Buy |
0 |
| Hold |
1 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | 2024 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -11.6m | 15.60% |
| EBITDA | -11.5m | 13.48% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €108.21 |
Number of shares | 1.24m |
52-week high/low | €0.0873 - €0.0000873 |
| Dividends | No |
Beta | 2.44 |
P/E ratio | 0.00 |
PEG ratio | 0.00 |
P/B ratio | 0.00 |
P/S ratio | 0.00 |
Company profile
| Name | Virpax Pharmaceuticals Inc Ordinary Shares |
| CEO | Jatinder Dhaliwal |
| Employees | 2 |
